Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Two cases of carcinoma in situ of the bladder treated with radical cystoprostatourethrectomy were evaluted by histologic study of the totally embedded epithelium. Clinical symptomatology consisted of urinary frequency with diminished bladder capacity and pain on voiding. Urinary cytology and multiple biopsies were essential for diagnosis of this lesion. The resected specimens of both cases were fixed in formalin and totally embedded for step sections that were mapped after histopathologic study. In both cases atypical epithelium and carcinoma in situ with foci of microinvasion affected the bladder mucosa and extended continuously to the distal ureters as well as the prostatic urethra. Since the lesion subsequently may result in invasive bladder cancer and often involves the prostatic urethra and distal ureter as in our cases the radical cystoprostatourethrectomy is recommended.
 ...
PMID:Non-papillary carcinoma in situ of the bladder: a clinicopathologic study of 2 cases treated with radical cystoprostatourethrectomy. 45 75

Inoperable bladder cancer and massive bleeding is an indication for selective bilateral transfemoral embolization of the internal iliac arteries. The method is preferred to the open ligation of these arteries. Histoacryl is the optimal material for longterm vascular embolization. In five patients with bleeding inoperable bladder cancer (stage T4N2) immediate and permanent haemostasis and a regression of pain was achieved.
 ...
PMID:[Selective transfemoral embolization of the internal iliac artery in carcinoma of the bladder (author's transl)]. 64 39

Between April, 1988 and August, 1990, the OmniPhase penile prosthesis, a non-inflatable self-contained penile prosthesis, was implanted in 34 patients, aged from 37 years to 79 years, averaging 54.2 years. The etiologies of the impotence were radical surgery for bladder cancer or rectal cancer in 17 patients, diabetes mellitus in 7 patients, vascular abnormality in 3 patients, spinal injury in 2 patients, penile disorders in 2 patients and others in 3 patients. Penile prosthesis was implanted by subcoronal incision under spinal or general anesthesia. Clinical results were evaluated 12 weeks after surgery. Thirty-two patients (94.1%) could have intercourse postoperatively. Eighteen patients (52.9%) were completely satisfied and 14 patients (41.2%) were satisfied, whereas one patient (2.9%) had no improvement and another patient (2.9%) deteriorated. There was no serious complication. However, prosthesis was explanted because of skin erosion in one patient. Pain, which lasted for more than 10 days, was seen in 3 patients (8.8%), penile edema in 11 patients (32.4%), and acute epididymitis in one patient. The obtained results showed that implantation of OmniPhase penile prosthesis is a safe and useful procedure for treatment of organic impotence.
 ...
PMID:[Implantation of self-contained non-inflatable penile prosthesis in patients with organic impotence]. 150 23

Twelve patients with superficial bladder cancer and carcinoma in situ of the bladder were treated with intravesically instilled BCG solution. As suggested by Pagano's group, we used BCG in a lower dose than usual hitherto (75 mg, strain Pasteur Paris). Complete tumor remission was obtained in all patients except the two whose treatment had to be discontinued at an early stage because of severe side effects. None of our patients was free of symptoms; pain or micturition, pollakiuria, gross hematuria, fever, swollen lymph nodes, and epididymitis occurred. We think, therefore, that low-dose therapy with BCG is as effective as full-dose therapy but the side effects are no less severe.
 ...
PMID:[Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?]. 156 32

Fourteen patients with invasive bladder cancer were treated by bilateral internal iliac artery infusion of cisplatin, with or without other anticancer agents, and concurrent radiotherapy. Angiotensin II was simultaneously infused in 10 cases. Of the 14 patients, complete response and partial response were achieved in 9 (64%) and 3, respectively. Hematuria was controlled in all 8 patients, and pain was relieved in 3 of 4 patients. Side effects were observed in 8 patients: appetite loss in 8, nausea and/or vomiting in 7, and leukocytopenia in 6 patients, in 3 of whom radiotherapy had to be intermittent because of severe leukocytopenia (less than 2000/mm3). However, restoration of leukocytopenia occurred one week later. Thus, intra-arterial anticancer agents including cisplatin together with concurrent radiation may be one of the most effective therapies for invasive bladder cancer.
 ...
PMID:[Combined treatment of invasive bladder cancer by intra-arterial infusion chemotherapy of cisplatin with or without other anticancer agents and concurrent radiotherapy--initial response and side effects]. 164 10

Fifteen patients with invasive bladder cancer were treated with selective intra-arterial cisplatin and external beam radiotherapy (30.6 Gy over 3 weeks) prior to a planned cystectomy. Cisplatin, in total 200 mg, was administered via bilateral internal iliac artery infusion during the course of radiotherapy. Seven patients were evaluated for local response. Partial response (PR) was revealed in 4, and minor response (MR) in 3. Ten patients received total cystectomy, and pathological effects by the criteria adipted by Japanese Urological Association and The Japanese Society of Pathology, were as follows: Ef. 3 in 1 case, Ef. 2 in 6. Ef. 1b in 1 and Ef. 1a in 2. Down staging was observed in 8 patients from the clinical to the pathological stage. Thirteen patients are alive for 21 months. Two patients have died (1 lung infarction, 1 pancreatic cancer). Though nausea and sciatica-like pain were observed in some cases, there was no severe systemic side effects such as bone marrow suppression and renal toxicity. From these results it is concluded that this therapeutic modality could be effective in the preoperative work-up of candidates for total cystectomy, and also that it could be useful in the treatment of patients in whom total cystectomy is contraindicated.
 ...
PMID:[Intra-arterial cisplatin and concurrent radiation for invasive bladder cancer]. 177 Jun 97

One hundred and three patients with moderate and severe cancer pain were given a sublingual analgesic agent--dihydroetorphine hydrochloride (DHE). Relief of cancer pain was moderate or complete in 89.3% (92/103). The average relief time (ART) was 3.9 hours and the average time before effectiveness was 20 minutes. In patients with acute or chronic cancer pain, moderate and complete pain-relief rates were 91.3% and 82.2% (P = 0.237). Difference of ART between them was insignificant (P = 0.299). The main clinical side-effects were somnolence (60%), dizziness (72%), nausea (30%), vomiting (16.5%), constipation (5%) and shortness of breath (8%). In two of the patients, the administration of DHE had to be stopped due to its side-effects. Age, sex and site of cancer pain were not related to the analgesic effects of DHE, but the pain-relief in patients with bladder cancer was poor (P less than 0.001). Within certain range, increase in dose was able to enhance its analgesic effect (P less than 0.001) and reduce drug resistance (P less than 0.001).
 ...
PMID:[Dihydroetorphine hydrochloride for moderate and severe cancer pain]. 188 41

Multi-institutional studies on clinical hyperthermia of deep-seated tumours were undertaken using 8 MHz radiofrequency capacitive heating devices (Thermotron RF-8) at seven institutions. Each institute was designated to treat specific organs. This paper contains the accumulations of the results obtained at different institutions charged for different tumours. Deep-seated tumours in the lung, stomach, pancreas, liver, urinary bladder and rectum were treated. A total of 177 cases examined from January 1985 to December 1988 included 96 cases (54%) treated with radiotherapy plus hyperthermia, among which 14 cases were pre-operative. Of 177 cases, 81 (46%) were treated with chemotherapy plus hyperthermia. Complete response (CR) and partial response (PR) were obtained in 80% of the cases with lung cancer, 39% with stomach cancer, 56% with liver cancer, 35% with pancreas cancer, 71% with urinary bladder cancer, 100% with primary rectal cancer, and 47% with recurrent rectal cancer. Thermometry was performed using two techniques; one is direct measurement of intratumour temperature in lung and liver cancers, the other is indirect measurement of intracavitary temperature for stomach, pancreas, urinary bladder and rectal cancers. Intratumour temperatures were measured in 30 of the 43 tumours of the lung and liver. The maximum tumour temperature was greater than 42 degrees C in 23 (77%) of the 30 tumours. Intracavitary temperatures were measured in 133 (99%) of the 134 tumours of stomach, pancreas, urinary bladder and rectum. An intracavitary temperature greater than 42 degrees C was obtained in 98 (73.7%) of the 133 tumours. The contribution of hyperthermia in improving the quality of life of patients under terminal care was also investigated. It was indicated that hyperthermia was one of the most effective treatment techniques for advanced or inoperable cases. In this study local control rate (LCR) was mainly discussed because the period of follow-up was only 3 years. Side-effects were observed in 37 cases (21%); main side-effects were fatty induration, pain during treatment and burn. However, no side-effects were severe enough to interrupt therapy.
 ...
PMID:Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. 220 48

Intravesical instillation therapy with (2"R)-4'-O-tetrahydropyranyl adriamycin [pirarubicin (THP)], a new anthracycline agent, was performed to examine its direct effect on superficial bladder cancer in a six-center cooperative Phase II study. There were 50 evaluable cases, for which a response rate of 50% was obtained. The main side effects that occurred were bladder irritation symptoms such as pollakisuria (50%) and pain on urination (38%). Intravesical pirarubicin instillation therapy was administered to eight cases that had not responded to doxorubicin therapy or that had experienced recurrence after such therapy. For six evaluable cases, the response rate was 50%, and the incidence of side effects was 88%.
 ...
PMID:Cooperative study of therapy of superficial bladder cancer by intravesical instillation of pirarubicin. 229 59

In an attempt to increase the therapeutic index of Cisplatin (CDDP), 29 continuous 48 hour intra-arterial (IA) infusions of 100-150 mg/m2 CDDP were given to 26 patients with bulky stage T3-T4 bladder cancer. Hypogastric artery catheters were placed distal (n = 42) or proximal (n = 7) to the origin of the superior gluteal artery. Atherosclerosis (n = 5) or aneurysm (n = 2) prevented successful IA catheter placement. Catheter maintenance resulted in no bleeding or thromboembolic episodes. Urethral catheters caused two urinary tract infections. Systemic toxicity was mild with on 4/29 infusions resulting in WBC less than 3,000, 3/29 infusions resulting in creatinine elevation, and 1/29 in peripheral neuropathy. Local effects of the IA CDDP included gluteal pain and ecchymosis (n = 1) and moderately disabling lower extremity neuropathies (n = 3). Systemic side effects of CDDP can be diminished by use of IA route of administration and slow continuous infusion.
 ...
PMID:Complications of hypogastric artery cisplatin infusions. 254 74


1 2 3 4 5 6 7 8 9 10 Next >>